Bangladesh vs Papua New Guinea: Population requiring preventive treatment for lymphatic filariasis
Bangladesh
3.21 million
in 2015
Papua New Guinea
4.50 million
in 2024
Bangladesh rank
18th
Papua New Guinea rank
16th
Population requiring preventive treatment for lymphatic filariasis over time
- Bangladesh
- Papua New Guinea
How they compare
Papua New Guinea currently reports 4.50 million against 3.21 million in Bangladesh, a difference of 1.29 million.
That makes Papua New Guinea's figure about 1.4 times Bangladesh's.
The two have swapped places 1 time across 9 shared years of data; in 2005 it was Bangladesh ahead.
Bangladesh ranks 18th and Papua New Guinea ranks 16th of 66 countries.
Bangladesh has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bangladesh | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 71.99 million | 4.78 million | 67.20 million | Bangladesh |
| 2010s | 47.96 million | 5.60 million | 42.35 million | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher population requiring preventive treatment for lymphatic filariasis, Bangladesh or Papua New Guinea?
- Papua New Guinea, at 4.50 million against 3.21 million in Bangladesh as of 2024.
- What is the difference in population requiring preventive treatment for lymphatic filariasis between Bangladesh and Papua New Guinea?
- 1.29 million, with Papua New Guinea ahead.
- How many years of comparable data are there for Bangladesh and Papua New Guinea?
- 9 years are reported by both, from 2005 to 2015.
- How do Bangladesh and Papua New Guinea rank globally for population requiring preventive treatment for lymphatic filariasis?
- Bangladesh ranks 18th and Papua New Guinea ranks 16th of 66 countries.
- Where does this data come from?
- Our World in Data, published as Population requiring preventive treatment for lymphatic filariasis. Statizoid refreshes it automatically from the source and publishes the full history for both places.